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Gamma-oryzanolNutraceuticals play an important role in cardiovascular prevention in patients with dyslipidemia. Many scientiﬁc
studies support the use of these substances alone or associated with other drugs in clinical practice. Speciﬁcally,
monacolines, berberine, policosanol and gamma-oryzanol could signiﬁcantly reduce cholesterolemia. However,
there is still an insufﬁcient number of studies demonstratingmorbidity andmortality outcomes of nutraceuticals,
nor are sufﬁcient data regarding the use of nutraceuticals in different types of patients, on tolerability, safety,
target population, modality and duration of use present in the literature.
© 2014 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cardiovascular diseases are the leading cause of mortality and mor-
bidity in the world: prevention of these diseases has therefore assumed
a relevant role in clinical practice. The LDL blood cholesterol is the most
known risk factor, so relevant that approximately 25% of the adult popu-
lation has abnormal levels. Cardiovascular disease risk is proportional to
blood cholesterol LDL levels, even in the range of values “high-normal”
(i.e. LDL-C between 130 and 160 mg/dL) [1,2].
Nutrients play an important role in maintaining the organism's
homeostasis to the dose taken with food, but some of them may have
speciﬁc active effects if supplemented with higher dosages.
The term nutraceutical means a natural substance derived from
food sources which, when taken alone or in concentrated form, has
well-known pharmacological properties. From an institutional point
of view, the only ofﬁcial deﬁnition of “nutraceutical” is that of the
Canadian Pharmacopoeia which deﬁnes it as an isolated or puriﬁed
food product which is generally sold in the form of pharmaceutical
drug not associated with food, and which must have proven physiolog-
ical beneﬁts or provides protection against chronic disease.
In order to be deﬁned efﬁciently, nutraceuticals must have a phar-
macological effectiveness that exceeds the spontaneous variance of
the parameter to be modiﬁed.
However, they must not be too effective so as not to be equated
to drugs, which is precisely why industries are not interested to invest
in primary outcome research (morbidity andmortality), but only in sec-
ondary outcomes or derivatives [3].sity Hospital Via Albertoni, 15
362843.
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are monacolin of fermented red rice, polycosanol and berberine.
Other substances have a less evident action (e.g. the active principles
of plants with cholagogue–choleretic action such as artichokes) or have
a good potential but have not yet adequately investigated (e.g. berga-
mot polyphenols, krill oil). The most efﬁcient nutraceuticals act on the
liverwhich impacts the lipidmetabolism, particularly the LDL cholester-
ol metabolism. Fibers and phytosterols, instead, taking action on the
intestinal absorption of cholesterol, appear to be of less impact on the
control of cholesterol blood levels [4].
2. Monacolin
Monacolins are fungal metabolites isolated fromMonascus purpureus
cultures, a contaminant responsible for the reddish color of rice upon
which they grow (so-called “fermented red rice”). There are several
kinds of monacolins; they have a complex molecular structure which is
very similar to that of natural statins, in particular to lovastatin. Their
metabolism is similar to that of the fat-soluble statins, which are quite
easily absorbed by the intestine as well as metabolized by the isoform
3A4 cytochrome P450 [5].
Like statins, monacolin functions through the reversible inhibition of
the hepatic enzyme which limits cholesterol synthesis, the 3-hydroxy-
3metil-glutarilCoenzimaA reductase. The cholesterol-lowering effect
of monacolin has been studied in a series of patient categories: hyper-
cholesterolemic, renal failure, HIV in highly-effective antiretroviral ther-
apy, post-infarction, and the elderly. In Italy a 3 mg dose of monacolin
extract is in use, with the limitation that the evaluating HPLC is able to
recognize and dose only a few types.
The administration of monacolin 3 mg/day obtains a maximum
reduction of 10–15% LDL cholesterol.C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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reducing blood cholesterol by the European Food Safety Authority
(EFSA), the percentage may reach 20%.
In addition, monacolins, like statins, have a role in the reduction of
high-sensitivity C-reactive proteins and improvement in ﬂow-mediated
dilation of the blood vessels. A clinical trial of secondary prevention inter-
vention conducted in China (Fig. 1) on a population of 4780 patientswith
coronary heart disease, of which 1445 over the age of 65, with follow-up
of 7 years, gave surprising results in terms of reducing the risk of lethal
and non-lethal recurrent events, probably compromised by the lack of
other active interventions on patients considered [6].
Although some studies have shown good tolerability of monacolins
by patients who are intolerant to statins [7], particular caution should
beusedwhen treating patientswithmyopathieswho take drugsmetab-
olized by cytochrome P450, especially those with a narrow therapeutic
range, such as cyclosporine. The low dosages used in Italy should not
create problems in patients with renal or liver diseases.
3. Berberine
Berberine is a highly concentrated natural alkaloid found in numer-
ous medicinal plants (Hydrastis canadensis, Coptis chinensis, Berberis
aquifolium, Berberis vulgaris, Berberis aristata). Its oral bioavailability is
low. The substance is metabolized by the liver and excreted primarily
via the bile after glucuronidation. The target organ is mainly the liver,
with a complex mechanism of action on all the metabolic structures,
which is still not fully understood (Fig. 2) [8].
Berberine probably inhibits the transcription of the mRNA encoding
the proprotein convertase subtilisin/kexina type 9 (PCSK9), which is the
protein that facilitates the separation of the hepatic LDL receptor from
the cell surface towards the lysosomes where it is usually degraded
with a resulting prolongation of the receptor's half-life, which can
then recapture more LDL cholesterol from the bloodstream to be sent
for disposal via the bile.
Berberine effects are clearly not dose-dependent: already 500 mg/
day achieves a reduction of approximately 20% of the LDL cholesterol
and 25% of triglycerides in pure hypercholesterolemics, in mixed
dyslipidemics, in type 2 diabetics and in hepatopathics [9]; its action
on insulin resistance in type 2 diabetics, is comparable to that obtained
with the full dose of metformin, which also shares the same gastro-
intestinal side effects [10].
Although there is a lack of important studies on the clinical out-
comes of this substance, preliminary data showhow it is able to increase
the number of circulating endothelial progenitor cells (direct laboratory
marker in vascular rejuvenation), reduce the number of circulatingFig. 1.Number needed to treat (NNT) a subjects in order to avoid a lethal coronary event, a
coronary event (any) or a death for any causes in adults and elderly in secundar preven-
tion treated with red yeast rice.endothelial microparticles (laboratory marker of endothelial dysfunc-
tion) and, ﬁnally, improve ﬂow-mediated vasodilatation (instrumental
marker of endothelial function) [11]. However, berberinemay interfere
with the metabolism of cyclosporine, but tolerability is generally high.
4. Polycosanols
Polycosanols are amixture of primary aliphatic saturated alcohols of
variable length, drawn from the wax of sugar cane, but also from bees-
wax, rice bran and other plants. The main components of the mixture
are octacosanols (ca. 60%), triacontanols (ca. 10%), esacosanols (approx.
6%), and other eptacontanols.
Polycosanols act through the inhibition of mRNA coding synthesis
for 3-hydroxy-3-methyl-glutarilCoenzyme A reductase [12]. The re-
sponse to these nutraceuticals is extremely variable because their
activity depends greatly on the polyalcohols prevailing in the mixture
administered. There are many clinical trials of a single Cuban research
center supporting the cholesterol lowering efﬁcacy of such molecules
which would be able to determine a decrease in LDL of up to 20% at a
dosage of 10 mg/day. However, more recent studies conducted on
different populations in Western Europe, patients with more severe
pathologies and probably different extracts of polycosanol, tend to
question their effective lipid-lowering ability. Tolerability seems good
in the short to medium terms [13].
5. Other active substances
The active ingredients of most herbal medicines for the reduction
of cholesterol (e.g., Allium sativum, Cynara scolimus, Sylibummarianum)
related to lipid-lowering (usually mild) are not known or are attributed
to the effectiveness of the plant complex.
Gamma-oryzanol extracted from rice bran seems to exert its mild
cholesterol-lowering action through a 4-component desmetil sterolica
interfering with the intestinal absorption of dietetic cholesterol [14,
15]. Bergamot-derived polyphenolic fraction seems to have a mild but
signiﬁcant cholesterol-lowering effect, accompanied by reductions of
malondialdehyde, oxyLDL receptor LOX-1 and phosphoPKB, which are
all biomarkers of oxidative vascular damage, in peripheral polymorpho-
nuclear cells [16].
The action mechanism is interesting, but there is still a great lack of
evidence of the cholesterol-lowering efﬁcacy in humans. High doses
(grams) of polyunsaturated fatty acids omega 3 and nicotinic acid mostly
reduce triglycerides,while the levo-carnitine only reduces lipoprotein (a).
6. Assembled products
In Italy the majority of nutraceuticals with lipid-lowering action
is commercially available in the form of composite, or association of
different substances at reduced dosage, assembled so as to exploit the
presumed synergy of the components.
There are various reasonswhy it might be preferable to commercial-
ize products of this kind: a) legal restrictions (e.g. you cannot use more
than 10 mg of monacolins/dose by law), b) side effects (e.g., doses of
berberine exceeding than 500mg/day aremore likely to cause gastroin-
testinal problems), and c) economic reasons (a more complex formula-
tion allows competitive differentiation and a possible saving on raw
material).
Sometimes this phenomenon leads to the creation of products
where there is no real rational association and the active substances
are under-dosed in relation to the lipid-lowering effect sought.
Therefore, before prescribing these nutraceuticals, it would be desir-
able to investigate the reliability of the origins of the raw materials,
dosage compatibility of the individual components with the desired
effectiveness, the rationality of the synergy in relation to the action
mechanism of the various formulations of substances, and the existence
of studies to conﬁrm the effectiveness of the association.
Fig. 2. Lipid-lowering mechanism of action of berberine.
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and polycosanol (10 mg), which has the rationale of combining an
inhibitor of the synthesis of the hydroxymethyl-glutaryl-coenzyme A
reductase (polycosanol) with an inhibitor of the activity (monacolin).
This associationwould apparently produce a reduction of LDL cholesterol
of about 15% [17,18].
Another preconceived association with a rational formulation com-
bines berberine with cholesterol synthesis inhibitors which facilitates
the disposal of circulating cholesterol (Fig. 3). This kind of addition
increases the cholesterol-lowering efﬁcacy (up to 25% reduction of
LDL cholesterol), also acting on triglycerides (−20%). Furthermore, it
has the advantage of having been proved effective in statin-intolerant
patients [19] and to have positive effects on indirectmarkers of vascular
health such as the ﬂow-mediated vasodilation and the carotid–femoral
pulse wave velocity [20].7. Conclusions
The use of substances derived from nutrients for lipid-lowering pur-
poses represents a viable alternative to conventional therapy which forFig. 3. Changes in ﬂow-mediated dilation after treatment with placebo or lipid-lowering
combined nutraceuticals.ethical and economic reasons cannot be administered to such a large
population affected by alterations in lipid metabolism, in the absence
of an elevated cardiovascular risk. However, in the face of a substantial
number of nutraceuticals with known efﬁcacy and safety on in vivo
and ex vivo models, only few substances have been adequately studied
in humans, especially in patients who are particularly vulnerable
such as pregnant women, the elderly, and patients with liver disease
or renal failure [21].References
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